- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05671848
Electroclinical Correlates in Essential Tremor (ECOLOVIM)
Study of the Activity of the Ventral Intermediate Nucleus of the Thalamus Under Ecological Conditions in Essential Tremor.
Essential tremor (ET) is a neurological disorder that affects nearly 0.9% of the world's population. High-frequency Deep Brain Stimulation (DBS) of the ventral-intermediate nuclei of the thalamus (VIM) has been proven as an effective second-line treatment for severe forms of ET.
The arrival on the market of the PERCEPT™ (new stimulator/recorder, Medtronic, Minneapolis, USA) now allows, in addition to the stimulation delivery, the recording of intracerebral activity at a distance from surgery, in a non-invasive way and in ecological condition at home. Investigators aim at recording the variations of thalamic Local Field Potentials (LFP) oscillations, in ecological condition, during rest and movement, with and without deep brain stimulation, once a week, between M3 and M6 post surgery.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Bordeaux, France, 33076
- CHU de Bordeaux
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Advanced disabling and drug-resistant tremor
- Receiving deep brain stimulation treatment with implantation of the PERCEPT™ device according to standard care
- Chronic progressive cardiac, renal, hematological or pulmonary diseases under treatment.
- Patient aged between 18 to 75 years
- Normal brain MRI
- MATTIS score ≥ 130/144 or MOCA ≥ 24/30
- Subject affiliated with or benefiting from a social security plan
- Free, informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research)
Exclusion Criteria:
- Major depressive syndrome (Beck scale > 20)
- MRI showing significant brain atrophy or significant hypersignals
- Pregnant or breastfeeding women
- Being unable to give personal consent
- Be subject to a measure of legal protection (curatorship, guardianship) or placed under judicial protection.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: experimental arm
Patient with ET and Receiving deep brain stimulation treatment with implantation of the PERCEPT™ device
|
Recordings of thalamic activity will be performed at home, in ecological conditions.
They will be realized during 4 distinct conditions each week between M3 and M6 post implantation: at rest and during tremor-induced movements.
For these recordings, stimulation will be either turned Off or On.
Three successive recordings of 30 seconds separated by 1 minute will be made for each condition.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Recorded signal quality
Time Frame: 6 months (M6) after surgery (M0)
|
The primary endpoint of this study will be the recorded signal quality, i.e., the ratio of signal amplitude (thalamic oscillations) to noise (artifacts) at least 3/1.
|
6 months (M6) after surgery (M0)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
presence or absence of brain oscillations
Time Frame: 6 months (M6) after surgery (M0)
|
Good reproducibility of the electrical signals based on the ability to visually individualize, from successive recordings, the presence or absence of brain oscillations in the different frequency bands of interest (peaks on the power spectrum).
For this purpose, the intra-patient reproducibility of the spectral powers at rest and in activity will be estimated using Cohen's Kappa coefficient and its two-sided 95% confidence interval according to the exact binomial law.
|
6 months (M6) after surgery (M0)
|
|
Power spectral density (PSD)
Time Frame: 6 months (M6) after surgery (M0)
|
Analysis of the amplitude of the average PSDs in the 2 distinct motor conditions (rest/movement) and in the 2 stimulation conditions (inactive/active).
A difference in PSD amplitude of 15% between the 4 situations is necessary to conclude to significant differences.
|
6 months (M6) after surgery (M0)
|
|
Location of the electrodes
Time Frame: 1 month (M1) after surgery (M0)
|
Position of the electrodes and the contacts used for the LFP recordings will be analyzed.
These contacts will need to be positioned in each VIM that are the targets of deep brain stimulation in the ET.
|
1 month (M1) after surgery (M0)
|
|
Evaluation of the efficacy of VIM DBS in the ET
Time Frame: 3 months (M3) after surgery (M0)
|
A 50% reduction in clinical scores at M3 compared to the pre-operative scores (M-1) is necessary to conclude that deep brain stimulation of VIM is significantly effective on tremor.
|
3 months (M3) after surgery (M0)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Dominique GUELH, Pr, University Hospital, Bordeaux
- Principal Investigator: Edouard COURTIN, Dr, University Hospital, Bordeaux
- Study Chair: Mahmoud HASSAN, Dr, MINDig
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHUBX 2022/29
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.